Key Points
- Jennifer Tousignant sold 2,272 shares of Viridian Therapeutics on Dec. 31 at an average price of $31.16, totaling $70,795.52, according to an SEC filing.
- In the latest quarter Viridian reported EPS of ($0.34) vs. ($0.82) expected and revenue of $70.57 million vs. $16.21 million expected, a massive year‑over‑year revenue increase, though the company still records negative net margin and return on equity.
- The stock opened at $30.68 (down ~1.4%), has a market cap of $2.93 billion and a one‑year range of $9.90–$34.04, while analysts maintain a consensus "Moderate Buy" with an average target around $41.75 after several recent price‑target raises.
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) insider Jennifer Tousignant sold 2,272 shares of the firm's stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total value of $70,795.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Viridian Therapeutics Trading Down 1.4%
Shares of VRDN opened at $30.68 on Friday. The firm has a 50 day simple moving average of $29.73 and a 200-day simple moving average of $22.34. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of -10.16 and a beta of 0.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.28 and a quick ratio of 11.28. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $34.04.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.82) by $0.48. Viridian Therapeutics had a negative return on equity of 78.50% and a negative net margin of 426.58%.The company had revenue of $70.57 million during the quarter, compared to analysts' expectations of $16.21 million. Viridian Therapeutics's revenue for the quarter was up 81993.0% on a year-over-year basis. Equities analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on the stock. Wall Street Zen raised shares of Viridian Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, November 8th. Royal Bank Of Canada increased their price objective on Viridian Therapeutics from $41.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, November 6th. The Goldman Sachs Group reiterated a "buy" rating and issued a $40.00 target price on shares of Viridian Therapeutics in a research note on Thursday, November 6th. Wedbush boosted their price target on Viridian Therapeutics from $42.00 to $47.00 and gave the company an "outperform" rating in a research note on Wednesday, December 10th. Finally, Needham & Company LLC lifted their price target on Viridian Therapeutics from $34.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday, December 23rd. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $41.75.
View Our Latest Stock Report on Viridian Therapeutics
Hedge Funds Weigh In On Viridian Therapeutics
Several hedge funds have recently made changes to their positions in VRDN. Aster Capital Management DIFC Ltd bought a new position in Viridian Therapeutics in the third quarter valued at approximately $35,000. Farther Finance Advisors LLC boosted its stake in shares of Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company's stock valued at $42,000 after buying an additional 1,491 shares during the period. Bessemer Group Inc. grew its stake in Viridian Therapeutics by 947.7% during the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company's stock worth $45,000 after buying an additional 1,886 shares in the last quarter. Larson Financial Group LLC bought a new position in shares of Viridian Therapeutics in the 3rd quarter valued at $52,000. Finally, US Bancorp DE grew its holdings in shares of Viridian Therapeutics by 23.2% during the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company's stock valued at $53,000 after purchasing an additional 463 shares during the last quarter.
Viridian Therapeutics Company Profile
(
Get Free Report)
Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.
In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
